Epoetin biosimilar

Pre-clinicalCompleted

0 watching 0 views this week💤 Quiet

Hype Score

Development Stage

Pre-clinical

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Chemotherapy-induced Symptomatic Anemia

Conditions

Chemotherapy-induced Symptomatic Anemia, Solid Tumors, Malignant Hemopathies, Lymphomas, Myelomas

Trial Timeline

Sep 1, 2009 → Aug 1, 2011

NCT ID

NCT02140736

About Epoetin biosimilar

Epoetin biosimilar is a pre-clinical stage product being developed by Pfizer for Chemotherapy-induced Symptomatic Anemia. The current trial status is completed. This product is registered under clinical trial identifier NCT02140736. Target conditions include Chemotherapy-induced Symptomatic Anemia, Solid Tumors, Malignant Hemopathies.

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (1)

NCT ID	Phase	Status	Start	Completion	Indication
NCT02140736	Pre-clinical	Completed	Sep 1, 2009	Aug 1, 2011	Chemotherapy-induced Symptomatic Anemia

Competing Products

20 competing products in Chemotherapy-induced Symptomatic Anemia

See all competitors

Product	Company	Stage	Hype Score
SON-080	Sonnet BioTherapeutics	Phase 1/2	36
Granisetron	Kyowa Kirin	Phase 3	77
ONO-7746	Ono Pharmaceutical	Phase 1	33
ONO-2910 + Placebo	Ono Pharmaceutical	Phase 2	52
PROCRIT 40,000 IU QW + Placebo	Johnson & Johnson	Phase 2	52
Hetrombopag Olamine + Hetrombopag Olamine ；Hetrombopag Olamine Placebo	Jiangsu Hengrui Medicine	Phase 3	77
Hetrombopag Olamine	Jiangsu Hengrui Medicine	Phase 2	52
Hetrombopag + Hetrombopag plus Placebo + Placebo	Jiangsu Hengrui Medicine	Phase 3	77
Hetrombopag + Matching placebo	Jiangsu Hengrui Medicine	Phase 3	77
Hetrombopag + Placebo	Jiangsu Hengrui Medicine	Phase 3	77
Fosaprepitant dimeglumine + Fosaprepitant Placebo + Dexamethasone + Ondansetron + Dexamethasone Placebo + Ondansetron Placebo + Rescue Therapy	Merck	Phase 3	77
Fosaprepitant	Merck	Phase 2	52
Fosaprepitant + Placebo for fosaprepitant + Ondansetron + Dexamethasone + 5-HT3 antagonist	Merck	Phase 3	77
Fosaprepitant + Dexamethasone + 5HT3	Merck	Phase 2	52
aprepitant + Comparator: Placebo to aprepitant + dexamethasone + granisetron + dexamethasone	Merck	Phase 3	77
aprepitant + Comparator: ondansetron + Comparator: dexamethasone + Comparator: fosaprepitant dimeglumine + Comparator; Placebo (unspecified) + Comparator; Placebo (unspecified)	Merck	Phase 3	77
EMEND	Merck	Pre-clinical	23
Fosaprepitant Dimeglumine + 5-HT3 antagonist + Dexamethasone	Merck	Approved	85
ondansetron clinical trial formulation + ondansetron marketed formulation	Merck	Phase 1	33
Aprepitant + Palonosetron + Dexamethasone	Merck	Phase 2	52

Other Products from Pfizer